The fourth annual awards program recognized top health and medical technology products and companies.
Healthcare company RxMx and pharmaceutical company Roche collaborated to produce a streamlined and simplified MS patient support program that helps manage treatments, keeps patients engaged, and reduces nurses’ workload.
According to RxMx, the app is called Conductor and was created specifically to assist MS patients being treated with the immunosuppressive therapy Ocrevus (ocrelizumab), which was approved in the United States in 2017. Ocrevus is marketed by Genentech, a member of the Roche Group.
The app automates administrative tasks to permit clinicians to engage with patients more effectively. Instead of relying solely on their healthcare team, for example, patients may use the app’s user-friendly interface to coordinate and schedule upcoming treatments, view the clinic’s location, and get key information about treatment. Patients also can get answers for common questions about MS and have direct access to patient support networks.
“We’re extremely proud of our work with Roche on the patient app,” George Hunnewell, RxMx CEO, said in a press release. “This program is incredibly successful in keeping patients engaged and adherent to their treatment, underscoring the need to support complex treatments with a digital companion app for patients.”
The app sends data to a back-end healthcare personnel portal that feeds the information directly to clinicians. While it does enable patients to contact a team nurse, the app frees nurses from administrative duties such as reminding patients of upcoming appointments.
Using a single platform, nurses are able to more accurately track and view the patient’s therapeutic journey, providing richer insight into the patient experience. Because the healthcare team has easy access to a patient’s treatment schedule, it can help them with treatment adherence.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?